LSTA Q3 2024 Earnings — Lisata Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

LSTALisata Therapeutics, Inc.

$44M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$5M

Net Income

-$5M

EPS (Diluted)

$-0.59

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$327,000

Balance Sheet

Total Assets

$38M

Total Liabilities

$5M

Stockholders' Equity

$34M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$5M	-$6M	+10.5%
Net Income	-$5M	-$5M	+6.3%